"
Team:Wageningen UR
From 2012.igem.org
TSlijkhuis (Talk | contribs) |
Jjkoehorst (Talk | contribs) |
||
| Line 37: | Line 37: | ||
<h2 class="ulc1">Abstract</h2> | <h2 class="ulc1">Abstract</h2> | ||
<h4>A standardized tool for site specific drug delivery using Virus-Like Particles</h4> | <h4>A standardized tool for site specific drug delivery using Virus-Like Particles</h4> | ||
| - | <p>Medicines are generally active in a non-site-specific fashion, affecting the whole patient, including healthy tissue. Therefore, we attempt to specifically target diseased areas by packaging medicines inside Virus-Like Particles (VLPs). VLPs are not infectious, as they are built solely from viral coat proteins. We designed a modular Plug and Apply system that enables modifications to these coat proteins. The system facilitates the linkage of numerous ligands to the coat protein, thereby creating site-specific carriers. After expression of coat protein genes in Escherichia coli the VLPs were assembled in vitro, yielding modified Virus-Like Particles. Medicines can be packed using the Plug and Apply system or simply by addition during VLP assembly. Concluding, VLPs can be used as universal carriers for site-specific drug delivery, allowing customization to a variety of diseases while decreasing side effects for patients during treatment.</p> | + | <p align="justify">Medicines are generally active in a non-site-specific fashion, affecting the whole patient, including healthy tissue. Therefore, we attempt to specifically target diseased areas by packaging medicines inside Virus-Like Particles (VLPs). VLPs are not infectious, as they are built solely from viral coat proteins. We designed a modular Plug and Apply system that enables modifications to these coat proteins. The system facilitates the linkage of numerous ligands to the coat protein, thereby creating site-specific carriers. After expression of coat protein genes in Escherichia coli the VLPs were assembled in vitro, yielding modified Virus-Like Particles. Medicines can be packed using the Plug and Apply system or simply by addition during VLP assembly. Concluding, VLPs can be used as universal carriers for site-specific drug delivery, allowing customization to a variety of diseases while decreasing side effects for patients during treatment.</p> |
<iframe width="305" height="229" src="http://www.youtube.com/embed/h-Db1gwOcTo?autoplay=1&rel=0&loop=1" frameborder="0" allowfullscreen></iframe> | <iframe width="305" height="229" src="http://www.youtube.com/embed/h-Db1gwOcTo?autoplay=1&rel=0&loop=1" frameborder="0" allowfullscreen></iframe> | ||
Revision as of 12:39, 11 September 2012
P'NAS
Coming soon...
VLPs' origins
Coming soon...
Outside modification
Coming soon...
Inside modification
Coming soon...
Applications
Coming soon...
Abstract
A standardized tool for site specific drug delivery using Virus-Like Particles
Medicines are generally active in a non-site-specific fashion, affecting the whole patient, including healthy tissue. Therefore, we attempt to specifically target diseased areas by packaging medicines inside Virus-Like Particles (VLPs). VLPs are not infectious, as they are built solely from viral coat proteins. We designed a modular Plug and Apply system that enables modifications to these coat proteins. The system facilitates the linkage of numerous ligands to the coat protein, thereby creating site-specific carriers. After expression of coat protein genes in Escherichia coli the VLPs were assembled in vitro, yielding modified Virus-Like Particles. Medicines can be packed using the Plug and Apply system or simply by addition during VLP assembly. Concluding, VLPs can be used as universal carriers for site-specific drug delivery, allowing customization to a variety of diseases while decreasing side effects for patients during treatment.
The Constructor
An application that assists you in creating your cloning strategies for your iGem project.
